Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas

This study has been terminated.
National Cancer Institute (NCI)
Information provided by:
Teva Pharmaceutical Industries Identifier:
First received: June 6, 2003
Last updated: May 20, 2011
Last verified: May 2011
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: April 2006
  Primary Completion Date: January 2006 (Final data collection date for primary outcome measure)